Indian cancer monoclonal antibodies market is estimated to grow at a CAGR of 12.5% during the forecast period. A significant rise in cancer incidences has been resulting in an increasing demand for monoclonal antibodies therapies in the country. As per the World Health Organization (WHO), in 2018, nearly 1.1 million new cancer incidences were reported in the country. In 2018, breast cancer accounted for 14.0%, lip, oral cavity (10.4%), cervix uteri (8.4%), lung (5.9%), stomach (5.0%), and other cancers (56.4%) of all new cancer incidences in the country. This leads to increasing demand for monoclonal antibody for cancer therapeutics which has shown to be more beneficial against some cancers compared to others. Some monoclonal antibodies used for cancer treatment are known as targeted therapy as they have a particular target on a cancer cell that intends to discover, attach to, and attack. However, some monoclonal antibodies work as immunotherapy as they support to make the response of the immune system better which in turn, supports the body to discover and attack cancer cells more potentially.
Get Free Sample link @ https://www.omrglobal.com/request-sample/indian-cancer-monoclonal-antibodies-market
Indian cancer monoclonal antibodies market is segmented based on type and application. Based on type, the market is classified into naked, conjugated, and others. Naked monoclonal antibodies are the most common form of antibodies used for the treatment of cancer. Most naked monoclonal antibodies bind to antigens that are normally multiple on the surface of cancer cells compared to healthy cells. The increasing number of biosimilars of naked monoclonal antibodies is further accelerating market growth. Based on the application, the market is classified into breast cancer, liver cancer, blood cancer, brain cancer, colorectal cancer, and others.
A full report of Indian cancer monoclonal Antibodies Market available @ https://www.omrglobal.com/industry-reports/indian-cancer-monoclonal-antibodies-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
Indian Cancer Monoclonal Antibodies Market by Type
- Naked
- Conjugated
- Others (Bispecific)
Indian Cancer Monoclonal Antibodies Market by Application
- Breast Cancer
- Liver Cancer
- Blood Cancer
- Brain Cancer
- Colorectal Cancer
- Others
Company Profiles
- AstraZeneca plc
- Biocon Ltd.
- Cadila Pharmaceuticals Ltd.
- Reddy’s Laboratories, Inc.
- Hoffmann-La Roche AG
- GlaxoSmithKline plc
- Intas Biopharmaceuticals Ltd.
- Lupin Ltd.
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
The Report Covers
- Comprehensive research methodology of the Indian cancer monoclonal antibodies market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Indian cancer monoclonal antibodies market.
- Insights about market determinants which are stimulating Indian cancer monoclonal antibodies market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/indian-cancer-monoclonal-antibodies-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
